Lincoln Pharmaceuticals Ltd

BSE: 531633 NSE: LINCOLN
Lincoln Pharmaceuticals Ltd - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L24230GJ1995PLC024288 Incorporated 20 January 1995 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: LINCOLN · BSE: 531633 Public Limited Company pharma
Data last updated
Market Cap
₹1,010 Cr
LINCOLN · NSE
Share Price
₹510.35
+1.19% today
Revenue
₹671 Cr
FY 2025-26 · +7.7% YoY
EBITDA
₹97.68 Cr
Margin 14.6%
Net Profit
₹87.89 Cr
FY 2025-26 · +8.5% YoY
P/E (TTM)
10.6x
P/B 1.3x
Authorised capital
₹32 Cr
Registered with MCA
Paid-up capital
₹20.03 Cr
Issued & subscribed

About Lincoln Pharmaceuticals Ltd

Data last updated:

Lincoln Pharmaceuticals Ltd is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 20 January 1995 and has been in existence for over 31 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1995PLC024288. Its GSTIN is 24AAACL2711N1ZO (Gujarat). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 531633 and NSE: LINCOLN.

The company has an authorised share capital of ₹32 Cr and a paid-up capital of ₹20.03 Cr. It is led by directors including Mahendrabhai Gulabdas Patel (Managing Director) and Hashmukhbhai Ishwarlal Patel (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Lincoln House Behind Satyam Complex Science City Road Sola, Ahmedabad, Gujarat, India – 380060.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹671.03 Cr, a growth of 7.7% compared to the previous year. For the same year it recorded a net profit of ₹87.89 Cr (net margin 13.1%) and EBITDA of ₹97.68 Cr (EBITDA margin 14.6%).

The company has about 1,531 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Lincoln Pharma. As per MCA filings, the company has open charges of ₹117.64 Cr and satisfied charges of ₹47 Cr on record. Court records list 94 cases involving the company, including 47 filed by the company and 47 filed against it; 10 cases are pending. The company has 107 deals on record (107 market trades); the latest was in April 2026. Its 8 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Baxter Pharmaceuticals India Private Limited with revenue of ₹671.53 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 1,757 overdue payments to 146 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lincolnpharma.com.

Company details

CIN L24230GJ1995PLC024288
Registration Number 024288
Incorporation Date 20 January 1995
ROC Ahmedabad
Listing Status Listed - Listed on NSE (LINCOLN); Listed on BSE (531633)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Mahendrabhai Gulabdas Patel Managing Director Hashmukhbhai Ishwarlal Patel Whole-Time Director Ashish Rajanikant Patel Whole-Time Director

Contact details

Lincoln Pharmaceuticals Ltd's registered office is in Ahmedabad, Gujarat. Its website is lincolnpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    lincolnpharma.com
  • Social Media
  • Registered Address
    Lincoln House Behind Satyam Complex Science City Road Sola, Ahmedabad, Gujarat, India – 380060
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Lincoln Pharmaceuticals Ltd, buy the company report.

Comprehensive company report
Lincoln Pharmaceuticals Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Lincoln Pharmaceuticals operates one associated brand: Lincoln Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Lincoln Pharma
Non-beta lactam pharmaceutical formulations are manufactured in various forms.lincolnpharma.com

Business activity

The main business activity of Lincoln Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Lincoln Pharmaceuticals Ltd, buy the company report.

Financials of Lincoln Pharmaceuticals Ltd

FY 2025-26 filings available

Lincoln Pharmaceuticals Ltd reported revenue of ₹671.03 Cr (up 7.7% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹671 Cr
+7.7% YoY
EBITDA
₹97.68 Cr
-3.8% YoY
Profit After Tax
₹87.89 Cr
+8.5% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue671623581510472424386
Revenue growth+7.7%+7.4%+13.8%+8.1%+11.3%+9.8%-
EBITDA97.6810199.9189.2195.4787.1865.54
EBITDA margin+14.6%+16.3%+17.2%+17.5%+20.2%+20.6%+17.0%
Profit before tax11610912210095.9383.7267.23
Net profit87.8981.0392.2572.5368.7462.3451.46
Net profit margin+13.1%+13.0%+15.9%+14.2%+14.6%+14.7%+13.3%
EPS (₹)43.8841.1146.5836.4034.6331.0825.72
Balance sheet
Total assets-678598509439371323
Net worth-672593502433366313
Total debt-0.001.072.002.040.525.07
Cash & bank-22.4313.8334.3218.8013.8414.58
Net working capital-220208206168153152
Cash flow
Cash from operations-93.0263.2239.2676.1369.2775.42
Cash from investing-(78.95)(57.34)(36.64)(78.08)(64.23)(30.88)
Cash from financing-(6.40)(5.18)(4.50)(2.56)(5.75)(37.76)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue191177187166163154168147
Revenue growth (YoY)+17.1%+15.1%+11.4%+13.5%+1.3%+4.6%--
Other income9.5324.26(4.20)15.157.2315.27(6.88)8.97
EBITDA23.6927.4324.8623.5925.4223.8126.7223.66
EBITDA margin+12.4%+15.5%+13.3%+14.2%+15.6%+15.5%+15.9%+16.1%
Depreciation3.883.883.683.723.623.483.233.22
Interest0.320.260.270.300.230.210.370.73
Profit before tax29.0247.5516.7134.7228.8035.3916.2428.68
Tax8.5911.325.076.128.837.714.677.92
Net profit20.4336.2311.6428.6019.9727.6811.5720.76
EPS (₹)10.2018.095.8114.289.9813.825.7810.37
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue671623581510472423376
Revenue growth+7.7%+7.4%+13.8%+8.1%+11.6%+12.5%-
EBITDA97.6810199.9189.1795.4687.0359.38
EBITDA margin+14.6%+16.3%+17.2%+17.5%+20.2%+20.6%+15.8%
Profit before tax11610912210095.9283.6664.06
Net profit87.8981.0392.2572.5268.7462.3349.61
Net profit margin+13.1%+13.0%+15.9%+14.2%+14.6%+14.7%+13.2%
EPS (₹)43.8841.1146.5836.4034.6331.0824.78
Balance sheet
Total assets-678598509439371313
Net worth-672593502433366304
Total debt-0.001.072.002.040.524.69
Cash & bank-21.9913.3933.8518.4313.4311.21
Net working capital-220208206168153130
Cash flow
Cash from operations-93.0263.2439.1676.1869.3970.71
Cash from investing-(78.95)(57.34)(36.64)(78.08)(64.39)(28.99)
Cash from financing-(6.40)(5.18)(4.50)(2.56)(5.74)(38.10)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue191177187166163154168147
Revenue growth (YoY)+17.1%+15.1%+11.4%+13.5%+1.3%+4.6%--
Other income9.5324.26(4.20)15.157.2315.27(6.88)8.97
Total expenses168150162143138130141123
EBITDA23.6927.4324.8623.5925.4223.8126.7223.66
EBITDA margin+12.4%+15.5%+13.3%+14.2%+15.6%+15.5%+15.9%+16.1%
Depreciation3.883.883.683.723.623.483.233.22
Interest0.320.260.270.300.230.210.370.73
Profit before tax29.0247.5516.7134.7228.8035.3916.2428.68
Tax8.5911.325.076.128.837.714.677.92

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 04 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue191177187166163154168147
Revenue growth (YoY)+17.1%+15.1%+11.4%+13.5%+1.3%+4.6%--
Other income9.5324.26(4.20)15.157.2315.27(6.88)8.97
EBITDA23.6927.4324.8623.5925.4223.8126.7223.66
EBITDA margin+12.4%+15.5%+13.3%+14.2%+15.6%+15.5%+15.9%+16.1%
Depreciation3.883.883.683.723.623.483.233.22
Interest0.320.260.270.300.230.210.370.73
Profit before tax29.0247.5516.7134.7228.8035.3916.2428.68
Tax8.5911.325.076.128.837.714.677.92
Net profit20.4336.2311.6428.6019.9727.6811.5720.76
EPS (₹)10.2018.095.8114.289.9813.825.7810.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue671623581510472424386
Revenue growth+7.7%+7.4%+13.8%+8.1%+11.3%+9.8%-
Other income33.4522.4834.4222.4710.005.6611.04
Total expenses573522481421377337321
Employee cost0.0011210393.1679.7263.2658.65
EBITDA97.6810199.9189.2195.4787.1865.54
EBITDA margin+14.6%+16.3%+17.2%+17.5%+20.2%+20.6%+17.0%
Depreciation14.5012.9010.629.178.097.567.33
Interest1.011.881.462.031.451.562.02
Profit before tax11610912210095.9383.7267.23
Tax27.7326.8528.9327.5826.5821.4715.77
Net profit87.8981.0392.2572.5368.7462.3451.46
Net profit margin+13.1%+13.0%+15.9%+14.2%+14.6%+14.7%+13.3%
EPS (₹)43.8841.1146.5836.4034.6331.0825.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-20.0320.0320.0320.0320.0320.00
Reserves & surplus-652573482413346293
Shareholders' funds (net worth)-672593502433366313
Minority interest-0.000.000.000.000.000.38
Secured loans-0.000.000.000.000.525.07
Unsecured loans-0.001.072.002.040.000.00
Total debt-0.001.072.002.040.525.07
Total liabilities-678598509439371323
Assets
Gross block-252237197171142147
Net block-182179151132111123
Capital work in progress-4.473.486.7116.051.690.04
Investments-17413991.3396.8180.6734.30
Inventories-78.6877.1770.0372.7446.6147.40
Sundry debtors-166162136116113101
Cash & bank balances-22.4313.8334.3218.8013.8414.58
Loans & advances-58.7146.1035.2048.5654.2850.47
Total current assets-326299276256228214
Total current liabilities-10691.2170.1488.4375.4761.36
Net working capital-220208206168153152
Total assets-678598509439371323
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-5.755.056.9311.4412.145.46
Net cash from operating activities-93.0263.2239.2676.1369.2775.42
Net cash from investing activities-(78.95)(57.34)(36.64)(78.08)(64.23)(30.88)
Net cash from financing activities-(6.40)(5.18)(4.50)(2.56)(5.75)(37.76)
Net change in cash-7.670.70(1.88)(4.50)(0.70)6.77
Closing cash-22.4313.8334.3218.8013.8414.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.7%+7.4%+13.8%+8.1%+11.3%+9.8%-
EBITDA growth-3.8%+1.6%+12.0%-6.6%+9.5%+33.0%-
PBT growth+5.9%-10.7%+21.7%+4.7%+14.6%+24.5%+8.1%
Net income growth+8.5%-12.2%+27.2%+5.5%+10.3%+21.1%-
Revenue CAGR (3Y)+9.6%+9.7%+11.0%+9.7%+8.8%+5.6%+2.4%
EBITDA CAGR (3Y)+3.1%+2.1%+4.7%+10.8%+12.4%+18.6%+11.9%
Profitability & leverage
Net income margin+13.1%+13.2%+16.1%+14.3%+14.7%+14.7%+13.3%
Return on capital employed-+17.4%+22.4%+21.6%+24.0%+24.6%+22.0%
Return on net worth-+13.0%+17.0%+15.6%+17.4%+18.3%+17.7%
Debt / equity-0.000.000.000.000.010.07
Long-term debt / equity-0.000.000.000.000.000.01
Interest cover1.212.121.642.541.661.963.47
Efficiency & per share
Fixed asset turnover-2.552.672.773.022.942.71
Inventory turnover-8.007.897.157.919.029.24
Debtors turnover-3.803.904.054.123.953.45
EPS (₹)43.8841.1146.5836.4034.6331.0825.72
Dividend per share (₹)1.801.801.801.501.501.501.50
Book value per share (₹)0.00335.34295.98250.86216.12182.92156.54
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue191177187166163154168147
Revenue growth (YoY)+17.1%+15.1%+11.4%+13.5%+1.3%+4.6%--
Other income9.5324.26(4.20)15.157.2315.27(6.88)8.97
Total expenses168150162143138130141123
EBITDA23.6927.4324.8623.5925.4223.8126.7223.66
EBITDA margin+12.4%+15.5%+13.3%+14.2%+15.6%+15.5%+15.9%+16.1%
Depreciation3.883.883.683.723.623.483.233.22
Interest0.320.260.270.300.230.210.370.73
Profit before tax29.0247.5516.7134.7228.8035.3916.2428.68
Tax8.5911.325.076.128.837.714.677.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue671623581510472423376
Revenue growth+7.7%+7.4%+13.8%+8.1%+11.6%+12.5%-
Other income33.4522.4834.4222.4810.005.7412.13
Total expenses573522481421377336317
Employee cost0.0011210393.1679.7263.2054.90
EBITDA97.6810199.9189.1795.4687.0359.38
EBITDA margin+14.6%+16.3%+17.2%+17.5%+20.2%+20.6%+15.8%
Depreciation14.5012.9010.629.178.097.565.47
Interest1.011.881.462.031.451.551.98
Profit before tax11610912210095.9283.6664.06
Tax27.7326.8528.9327.5626.5721.4214.48
Net profit87.8981.0392.2572.5268.7462.3349.61
Net profit margin+13.1%+13.0%+15.9%+14.2%+14.6%+14.7%+13.2%
EPS (₹)43.8841.1146.5836.4034.6331.0824.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-20.0320.0320.0320.0320.0320.00
Reserves & surplus-652573482413346284
Shareholders' funds (net worth)-672593502433366304
Secured loans-0.000.000.000.000.524.69
Unsecured loans-0.001.072.002.040.000.00
Total debt-0.001.072.002.040.524.69
Total liabilities-678598509439371313
Assets
Gross block-252237197171142108
Net block-18217915113211191.03
Capital work in progress-4.473.486.7116.051.690.04
Investments-17413991.3896.8680.7260.00
Inventories-78.6877.1770.0372.7446.6137.54
Sundry debtors-16616113511511291.00
Cash & bank balances-21.9913.3933.8518.4313.4311.21
Loans & advances-59.8347.2236.3249.5455.3241.41
Total current assets-326299276256227181
Total current liabilities-10691.0769.9888.1974.9151.30
Net working capital-220208206168153130
Total assets-678598509439371313
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-5.314.586.5711.0311.775.31
Net cash from operating activities-93.0263.2439.1676.1869.3970.71
Net cash from investing activities-(78.95)(57.34)(36.64)(78.08)(64.39)(28.99)
Net cash from financing activities-(6.40)(5.18)(4.50)(2.56)(5.74)(38.10)
Net change in cash-7.670.73(1.99)(4.46)(0.74)3.61
Closing cash-21.9913.3933.8518.4313.4311.21
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.7%+7.4%+13.8%+8.1%+11.6%+12.5%-
EBITDA growth-3.8%+1.6%+12.0%-6.6%+9.7%+46.6%-
PBT growth+5.9%-10.7%+21.7%+4.7%+14.7%+30.6%+10.2%
Net income growth+8.5%-12.2%+27.2%+5.5%+10.3%+25.6%-
Revenue CAGR (3Y)+9.6%+9.7%+11.1%+10.7%+10.2%+9.2%+7.3%
EBITDA CAGR (3Y)+3.1%+2.1%+4.7%+14.5%+16.5%+23.7%+11.8%
Profitability & leverage
Net income margin+13.1%+13.2%+16.1%+14.3%+14.7%+14.7%+13.2%
Return on capital employed+16.1%+17.4%+22.4%+21.6%+24.0%+24.9%+21.5%
Return on net worth+12.3%+13.0%+17.0%+15.6%+17.4%+18.6%+17.5%
Debt / equity0.000.000.000.000.000.010.07
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover1.212.121.642.541.661.953.67
Efficiency & per share
Fixed asset turnover2.552.552.672.773.023.383.61
Inventory turnover8.458.007.897.157.9110.0511.22
Debtors turnover4.123.823.924.074.164.163.69
EPS (₹)43.8841.1146.5836.4034.6331.0824.78
Dividend per share (₹)1.801.801.801.501.501.501.50
Book value per share (₹)0.00335.34295.98250.86216.12182.92152.25

To see the full year-wise statements and ratios of Lincoln Pharmaceuticals Ltd, buy the company report.

Board of directors of Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals has 9 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Hashmukhbhai Ishwarlal Patel
Also directs: Zullinc Healthcare LLP, Cosmetics Concept Research Private Limited
Whole-Time Director20 Jan 199531 Years 9 MonthsCurrent
Ashish Rajanikant PatelWhole-Time Director14 Nov 201411 Years 11 MonthsCurrent
Munjal Mahendrabhai Patel
Also directs: Downtown Travels LLP, Downtown Finance Private Limited, Sunmed Corporation LLP and 1 more
Whole-Time Director14 Nov 201411 Years 11 MonthsCurrent
Saurin Jagdish Bhai Parikh
Also directs: Global Park Developer LLP, Universal Industrial Park LLP, Pashupati Texspin Export LLP and 5 more
Director27 Mar 20188 Years 7 MonthsCurrent
Rajanikant Gulabdas PatelDirector01 Oct 200818 Years 1 MonthsCurrent
Kishor Meghji Shah
Also directs: Downtown Finance Private Limited
Director16 Aug 199531 Years 2 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Peer comparison

Lincoln Pharmaceuticals Ltd is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Baxter Pharmaceuticals India Private Limited₹671.53 Cr (FY 2025)20.0%Vasana Chacharwadi, Gujarat, India
Lincoln Pharmaceuticals Ltdthis company₹671.03 Cr (FY 2026)₹87.89 Cr13.1%7.7%1,531Ahmedabad, Gujarat, India
Venus Remedies Limited₹668.84 Cr (FY 2025)9.0%Chandigarh, India
Tablets (India) Ltd₹667.39 Cr (FY 2025)9.0%Chennai, Tamil Nadu, India
RPG Life Sciences Limited₹666.11 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Theon Pharmaceuticals Limited₹633.1 Cr (FY 2025)4.0%Chandigarh, India
Kopran Limited₹629.2 Cr (FY 2024)14.0%Mumbai, Maharashtra, India
Malladi Drugs and Pharmaceuticals Limited₹626.79 Cr (FY 2025)-7.0%Chennai, Tamil Nadu, India
Samarth Life Sciences Private Limited₹624.79 Cr (FY 2025)11.0%Mumbai, Maharashtra, India

To see the full peer comparison of Lincoln Pharmaceuticals Ltd, buy the company report.

Auditor

Lincoln Pharmaceuticals Ltd is audited by SAMIR M. SHAH & ASSOCIATES for the financial year 2024.

Auditor firmFinancial yearFirm registration number
SAMIR M. SHAH & ASSOCIATESFY 2024122377W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 49.80%, foreign institutional investors hold 4.60%, domestic institutional investors hold 0.30% and retail and other public shareholders hold 45.40%.

Promoters: 49.80%DII (Domestic Institutional): 0.30%FII (Foreign Institutional): 4.60%Retail & Others: 45.40%
Sep 2026
QUARTER
49.80% Promoters
0.30% DII (Domestic Institutional)
4.60% FII (Foreign Institutional)
45.40% Retail & Others
Promoter holding - history
Now 49.80% · Sep 2026High 49.80% · Dec 2025Low 49.80% · Dec 2025
48%48.8%49.5%50.3%51%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 49.80%Mar 2026: 49.80%Jun 2026: 49.80%Sep 2026: 49.80%49.80%49.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters49.80%49.80%49.80%49.80%
Public50.20%50.20%50.20%50.20%

Charges & borrowings

Open charges
₹117.64 Cr
Satisfied charges
₹47 Cr
Breakdown by lending institutions
State Bank of India₹117.64 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
03 Nov 199990096639State Bank of India₹58.82 CrOpen
20 Mar 199990101919State Bank of India₹58.82 CrOpen
24 Sep 201510595490Yes Bank Limited₹10 CrSatisfied
19 May 201510573870Yes Bank Limited₹13 CrSatisfied
29 Sep 201010248911Idbi Bank Limited₹20 CrSatisfied

To see the full charge records of Lincoln Pharmaceuticals Ltd, buy the company report.

Total charge records: 6 View all charges

Deals & funding

Lincoln Pharmaceuticals Ltd has 107 deals on record (107 market trades); the latest was in April 2026.

Total deals
107
Market trades
107

Deals on record (5 of 107)

WhenDealAmountParties
Apr 2026Market trade₹22.46 CrBuyer: NK Securities Research Private Limited , Qe Securities LLP
Seller: NK Securities Research Private Limited , Qe Securities LLP
Aug 2025Market trade₹7.56 CrBuyer: Irage Broking Services LLP
Seller: Irage Broking Services LLP
Aug 2025Market trade₹34.5 CrBuyer: NK Securities Research Private Limited , Musigma Securities, Irage Broking Services LLP
Seller: NK Securities Research Private Limited , Musigma Securities, Irage Broking Services LLP
Sep 2024Market trade₹10.3 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Nov 2023Market trade₹12.98 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP

To see the full deal history of Lincoln Pharmaceuticals Ltd, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Lincoln Pharmaceuticals Ltd has 14 MSME Form 1 returns on record between 2019 and 2024, listing 1,757 overdue payments to 146 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 146)

SupplierAmount dueDue sinceReported on
an individual supplier
Glacier Tek.Service
Pharma Synth Formulations Limited
an individual supplier
an individual supplier

To see the full MSME payment records of Lincoln Pharmaceuticals Ltd, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Lincoln Pharmaceuticals Ltd has a workforce of 1,531 employees on its EPFO records as of Feb 25, 2025, across 2 active EPFO establishments.

Employee count
1,531
Active EPFO establishments
2
Employee growth
4.72%

GST

Lincoln Pharmaceuticals has 3 GST registrations: 1 active and 2 cancelled or inactive.

Total GSTINs
3
Active
1
Cancelled / inactive
2
GSTINStateStatusRegistered on
24AAACL2711N1ZOGujaratActive01 Jul 2017

To see the full GST registrations and return filing status of Lincoln Pharmaceuticals Ltd, buy the company report.

Recent activity

Lincoln Pharmaceuticals Ltd has 25 board changes on record since 1995: 17 appointments and 8 cessations. The latest: Nareshkumar Pirabhai Suthar was appointed as Director on 01 Apr 2024.

Filing
Lincoln Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Lincoln Pharmaceuticals Ltd last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Appointed
Nareshkumar Pirabhai Suthar was appointed as Director.
Appointed
Seema Manubhai Mehta was appointed as Director.
Ceased
Pirabhai Ramjibhai Suthar ceased to be Director.
Ceased
Meha Patel ceased to be Director.
Ceased
Anand Arvindbhai Patel ceased to be Whole-Time Director.
Ceased
Ishwarlal Ambalal Patel ceased to be Director.
Ceased
Niren Atinbhai Desai ceased to be Nodal Officer.
Appointed
Anand Arvindbhai Patel was appointed as Whole-Time Director.
Ceased
Arvindbhai Gulabdas Patel ceased to be Director.
Charges
A charge registered on 19 May 2015 via Charge ID 10573870 with Yes Bank Limited was fully satisfied on 29 Apr 2021.

28 earlier events are in the company report.

News

LINCOLN: Q2 SL NET PROFIT 204M RUPEES VS 200M (YOY)
29 Oct 2026 · Exchange Update
LINCOLN: Q2 REVENUE 1.9B RUPEES VS 1.6B (YOY)
29 Oct 2026 · Exchange Update
LINCOLN: Q2 EBITDA 237M RUPEES VS 254M (YOY); Q2 EBITDA MARGIN 12.4% VS 15.6% (YOY)
29 Oct 2026 · Exchange Update

Frequently asked questions

Lincoln Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 20 January 1995 (31+ years old) and is registered under CIN L24230GJ1995PLC024288. Listed on BSE: 531633 and NSE: LINCOLN.

Lincoln Pharmaceuticals reported revenue of ₹671.03 Cr for FY 2025-26 (up 7.7% YoY) based on consolidated financials.

Lincoln Pharmaceuticals has 9 current directors:

The latest financial statements of Lincoln Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Lincoln Pharmaceuticals is 24AAACL2711N1ZO, registered in Gujarat. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.

The CIN (Corporate Identification Number) of Lincoln Pharmaceuticals is L24230GJ1995PLC024288. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Lincoln Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 531633) and NSE (symbol: LINCOLN).

Lincoln Pharmaceuticals has 94 court cases on record: 47 filed by the company and 47 filed against it. 10 are pending. Most are in the high courts.

Lincoln Pharmaceuticals was incorporated on 20 January 1995, making it 31+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Lincoln Pharmaceuticals has 107 deals on record (107 market trades); the latest was in April 2026.

The peers of Lincoln Pharmaceuticals by revenue are Baxter Pharmaceuticals India Private Limited, Venus Remedies Limited, Tablets (India) Ltd, RPG Life Sciences Limited, Theon Pharmaceuticals Limited and 3 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Nareshkumar Pirabhai Suthar was appointed as Director on 01 Apr 2024. Seema Manubhai Mehta was appointed as Director on 01 Apr 2024. Pirabhai Ramjibhai Suthar ceased to be Director on 31 Mar 2024. Lincoln Pharmaceuticals has 25 board changes on record in total.